Acrivon Therapeutics, Inc. ( (ACRV) ) has released its Q4 earnings. Here is a breakdown of the information Acrivon Therapeutics, Inc. presented to its investors.
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines using its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to discover and design drug candidates tailored to patients whose tumors are predicted to be sensitive to specific treatments.
In its latest earnings report, Acrivon Therapeutics highlighted significant progress in its clinical programs, particularly in the development of ACR-368 for endometrial cancer, which shows promising results in heavily pretreated patients. The company also reported its financial results for the fourth quarter and full year of 2024, detailing increased research and development expenses as it advances its pipeline.
Key financial metrics revealed a net loss of $22.8 million for the fourth quarter and $80.6 million for the full year 2024, reflecting increased investment in research and development. The company has extended its cash runway into 2027, supported by cash, cash equivalents, and investments totaling $184.6 million as of December 31, 2024. Acrivon is prioritizing its resources on endometrial cancer due to the limited treatment options available and the compelling commercial opportunity.
Strategically, Acrivon is advancing its ACR-368 and ACR-2316 programs, with the former showing a confirmed overall response rate of 35% in OncoSignature-positive endometrial cancer patients. The company is also progressing with its Phase 1 trial of ACR-2316, observing tumor shrinkage at the third dose level, and plans to provide updates on its registrational intent trial and confirmatory trial design for ACR-368.
Looking ahead, Acrivon Therapeutics is focused on achieving key milestones, including reporting initial clinical data from its ongoing trials and advancing its drug discovery programs. The company remains committed to leveraging its AP3 platform to optimize therapeutic compounds and expand its pipeline, positioning itself for future growth in the precision oncology sector.